Premium
Progress in HPV vaccination in low‐ and lower‐middle‐income countries
Author(s) -
LaMontagne D. Scott,
Bloem Paul J.N.,
Brotherton Julia M.L.,
Gallagher Katherine E.,
Badiane Ousseynou,
Ndiaye Cathy
Publication year - 2017
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.12186
Subject(s) - low and middle income countries , vaccination , economic growth , human papillomavirus , sustainability , political science , momentum (technical analysis) , global health , medicine , scale (ratio) , developing country , family medicine , business , geography , health care , economics , virology , finance , ecology , cartography , biology
Abstract The past 10 years have seen remarkable progress in the global scale‐up of human papillomavirus (HPV) vaccinations. Forty‐three low‐ and lower‐middle‐income countries (LLMICs) have gained experience in delivering this vaccine to young adolescent girls through pilot programs, demonstration programs, and national introductions and most of these have occurred in the last 4 years. The experience of Senegal is summarized as an illustrative country case study. Publication of numerous delivery experiences and lessons learned has demonstrated the acceptability and feasibility of HPV vaccinations in LLMICs. Four areas require dedicated action to overcome remaining challenges to national scaling‐up: maintaining momentum politically, planning successfully, securing financing, and fostering sustainability. Advances in policy, programming, and science may help accelerate reaching 30 million girls in LLMICs with HPV vaccine by 2020.